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During 2010–2014, we enrolled 511 patients with suspected 
bacterial meningitis into surveillance in 2 districts of north-
ern Togo. We identified 15 persons with Streptococcus suis 
infection; 10 had occupational contact with pigs, and 12 suf-
fered neurologic sequelae. S. suis testing should be consid-
ered in rural areas of the African meningitis belt.
Streptococcus suis, an encapsulated, gram-positive bac-terium, commonly colonizes the respiratory, genital, 
and intestinal tracts of pigs and may cause severe dis-
ease, including meningitis, sepsis, and bronchopneumonia 
(1). Zoonotic cases of S. suis invasive disease have been 
documented in Europe, Asia, the Americas, and Oceania 
among persons in direct contact with pigs or pork meat; 
the case-fatality rate is 10%–20%, and neurologic sequelae 
frequently occur (2–4). Two large outbreaks have occurred 
in China (5,6), but little is known about the disease among 
humans in Africa.
We began surveillance in May 2010 for acute bacterial 
meningitis in hospitals in 2 rural districts in Togo. The Na-
tional Ethical Committee of Togo reviewed and approved 
our study protocols.
The Study
During 2010–2014, we conducted surveillance for pa-
tients with signs and symptoms of meningitis at 5 hospitals 
in northern Togo: 4 in Dapaong, Tône District, and 1 in 
Cinkassé, Cinkassé District. These districts are within the 
African meningitis belt and experience annual outbreaks of 
hyperendemic bacterial meningitis during the dry season 
(November–April) and generalized epidemics every 4–6 
years (7). Lumbar puncture was performed at admission on 
all patients with suspected meningitis, provided informed 
consent had been given. Cerebrospinal fluid (CSF) speci-
mens were transferred to the regional bacteriology labora-
tory in Dapaong for cytologic testing, Gram staining, latex 
agglutination, and culture. CSF samples were further tested 
by conventional PCR at Centre Muraz Laboratory (Bobo-
Dioulasso, Burkina Faso) or Institut National d’Hygiène 
(Lomé, Togo) for identification of S. pneumoniae, Neisse-
ria meningitidis, and Haemophilus influenzae type b (Hib).
Beginning in August 2011, Streptococcus isolates 
from Dapaong were stored at –80°C in STGG (skim milk, 
tryptone, glucose, glycerol) medium and sent to the Nation-
al Reference Center for Streptococci (Aachen, Germany) 
for confirmatory testing. In April 2013, after the reference 
laboratory identified several cases of S. suis infection, the 
bacteriology laboratory in Dapaong implemented addi-
tional diagnostic testing using the API Kit (bioMérieux, 
Marcy l’Etoile, France) to enable rapid case detection by 
culture. For species confirmation and molecular typing, 
we sequenced the genome of S. suis isolates by using the 
Nextera XT DNA Library Preparation Kit (Illumina, San 
Diego, CA, USA) and the MiSeq Reagent Kit v3 (Illumina) 
for 2 × 300-bp paired-end reads. We deposited sequence 
data in the European Nucleotide Archive (accession no. 
PRJEB12952).
In June 2014, we visited all identified S. suis menin-
gitis case-patients and used a questionnaire to collect data 
on their environments and contact with pigs and pork meat. 
Thereafter, we prospectively administered the question-
naire to new case-patients. We used Stata 12 (StataCorp 
LP, College Station, TX, USA) to analyze the data. 
During August 2010–July 2014, we enrolled 511 per-
sons with suspected bacterial meningitis, of whom 126 
(24.6%) were <5 years of age. We performed lumbar punc-
ture on 489 enrollees: 89 were positive for S. pneumoniae, 
60 for N. meningitidis, 15 for S. suis, 9 for Streptococcus 
sp., 8 for Hib, and 7 for other identified pathogens; 301 
had no identified etiology. S. suis–positive cases were con-
firmed by genome sequence analysis of the isolates, using 
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Kraken (8) and comparative analyses with reference S. suis 
genomes (9) and other outlier species. We predicted that all 
15 S. suis isolates were serotype 2 due to 100% coverage of 
the associated capsular polysaccharide loci sequence (10); 
6 were sequence type 1, and 11 were a single-locus variant 
of sequence type 1 exhibiting a new recA allele sequence 
(http://ssuis.mlst.net/).
S. suis cases peaked in April through August each year 
(Figure). Of the 15 S. suis patients, 3 were 5–14 years of 
age, 7 were 30–49 years of age, and 5 were >50 years of 
age; 12 (80%) patients were male (Table 1). Median time 
from symptom onset to hospitalization was 2 days (inter-
quartile range 1–4 days), similar to the time for patients 
with meningitis caused by other pathogens. One (6.7%) 
patient died; 12 (85%) of the 14 survivors had neurologic 
sequelae (Table 1). Resistance to antimicrobial drugs was 
relatively uncommon (Table 2).
All 15 S. suis meningitis patients were involved in pig 
farming or slaughtering or had a family member who was: 
3 each were pig farmers only or butchers only, 3 were pig 
farmers and involved in slaughtering, and 6 had a family 
member engaged in 1 of these activities. Twelve patients 
reported handling pig meat during cooking; 14 reported 
eating pork (9 at least once per week). Three patients re-
ported that a family member or neighbor had also contract-
ed meningitis and had subsequent hearing loss.
Conclusions
In the area of Togo under surveillance, meningitis cases 
peak during the dry season, and S. pneumoniae and N. 
meningitidis have been the leading causal agents since 
the introduction of Hib conjugate vaccine in 2008. During 
2010–2014, we identified 15 cases of S. suis meningitis, 
representing 3.1% of all suspected bacterial meningitis cas-
es and 8.0% of etiologically confirmed cases. These num-
bers are probably an underestimate because to identify S. 
suis, we relied on culture only, whereas we used CSF PCR 
to test for other bacteria. Furthermore, 9 Streptococcus iso-
lates did not survive to be sent for confirmatory testing and 
may represent additional S. suis cases.
Our investigation showed that two thirds of S. suis 
meningitis patients were involved in pig farming or slaugh-
tering, and the remainder had a family member who was 
involved in these activities. Most case-patients regularly 
cooked and ate pork. S. suis meningitis cases appear to 
have a seasonal pattern, clustering in May–July, a period 
of intensive slaughtering, during which pigs are confined 
to pens, and run-off water accumulates nearby in open-air 
pits. Slaughtering is conducted in butcher shops, where 
carcasses remain for several days. Approximately 30 pork 
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Figure. Streptococcus suis and other Streptococcus spp. 
infections identified per month through acute bacterial meningitis 
surveillance in northern Togo, 2010–2014.
 
 
 
Table 1. Characteristics of patients from 2 rural districts with meningitis caused by various pathogens, Togo, 2010–2014 
Characteristic 
No. (%) case-patients infected with No. (%) all 
case-patients, 
N = 489 S. suis, n = 15 
Other Streptococcus 
sp., n = 9 
S. pneumoniae, 
n = 89 
Other infections, 
n = 75* 
No etiologic 
agent, n = 301 
Age, y       
 <5 0 3 (33) 12 (13) 22 (29) 84 (28) 121 (25) 
 5–14 3 (20) 0 34 (38) 36 (48) 74 (25) 147 (30) 
 15–29 0 2 (22) 23 (26) 7 (9) 65 (22) 97 (20) 
 30–49 7 (47) 4 (44) 13 (15) 8 (11) 52 (17) 84 (17) 
 >50 5 (33) 0 7 (8) 2 (3) 26 (9) 40 (8) 
Sex       
 M 12 (80) 6 (67) 42 (47) 39 (52) 156 (52) 255 (52) 
 F 0 (0) 3 (33) 47 (53) 36 (48) 145 (48) 244 (48) 
Died 1 (7) 1 (11) 29 (33) 5 (7) 41 (14) 77 (16) 
Sequelae       
 Any† 12 (80) 2 (22) 17 (19) 5 (7) 27 (9) 63 (13) 
 Hearing loss‡ 8 (67) 1 (50) 8 (47) 3 (60) 4 (15) 24 (5) 
 Paralysis‡ 2 (17) 1 (50) 3 (18) 2 (40) 6 (22) 14 (3) 
 Visual impairment‡ 5 (42) 0 2 (12) 0 1 (4) 8 (2) 
 Seizure disorder‡ 0 0 0 0 2 (7) 2 (0) 
*Includes 60 case-patients with Neisseria meningitidis, 11 with Haemophilus influenzae, 1 with Escherichia coli, 1 with Staphylococcus aureus, 1 with 
Streptococcus pyogenes, and 1 undetermined. 
†Percentages calculated among all patients. 
‡Percentages calculated among patients with sequelae. 
 
DISPATCHES
butchers work in Dapaong, and overall, >1,000 pigs are 
slaughtered in Tône District each year (G. A. Boukaya, 
Direction Régionale de l’Agriculture, de l’Elevage et de 
la Pêche des Savanes, pers. comm., 2015 Aug 1). Based 
on these data, the cumulative incidence of S. suis meningi-
tis among Dapaong butchers during 2010–2014 was 20% 
(6 cases/30 butchers), compared with 0.00375% (15 cas-
es/400,000 total population) in Tône and Cinkassé Districts 
(incidence rate ratio 5,333). Although this was not a rigor-
ously controlled prospective study, our results are highly 
suggestive of an association between butchering pigs and 
acquisition of S. suis meningitis; pig contact through farm-
ing or cooking may also be a risk factor. Three patients 
reported that a close contact had also contracted meningi-
tis; these cases probably reflect acquisition from a shared 
environmental source.
We plan to continue laboratory testing for S. suis 
among patients enrolled in bacterial meningitis surveil-
lance in northern Togo and investigating risk factors 
among confirmed case-patients. Biochemical testing for 
speciation of Streptococcus spp. is rarely part of routine 
bacteriologic evaluation of CSF in Africa and was not 
done at our site before the initial identification of several 
S. suis cases. S. suis testing should be considered for men-
ingitis patients in areas of rural Africa where pig farming 
is common. All S. suis isolates in our study were suscep-
tible to ceftriaxone, the presumptive therapy for nonepi-
demic meningitis in the meningitis belt; consequently, our 
findings do not suggest a need for altering current thera-
peutic guidelines. To reduce the incidence of S. suis men-
ingitis, future efforts should first more fully delineate the 
practices that increase the risk for infection and then be 
directed toward educational campaigns targeting groups 
at high risk.
Dr. Tall is an epidemiologist and project coordinator at AMP in 
Ouagadougou, Burkina Faso. She has coordinated a meningitis 
and pneumonia surveillance study in northern Togo since 2011 
and focuses on building country capacity for bacterial meningitis 
case–based surveillance in the African meningitis belt. 
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Table 2. Antimicrobial resistance patterns of Streptococcus suis and other Streptococcus spp. isolates from meningitis patients in 2 
rural districts in northern Togo, 2010–2014 
Antimicrobial drug 
No. S. suis samples tested/no. (%) susceptible  No. other Streptococcus spp. 
samples tested/no. (%) susceptible Tested at local laboratory* Tested at reference laboratory† 
Amoxicillin 15/15 (100) 11/10 (91) 9/5 (56) 
Cefotaxime 0 11/10 (91) 0 
Ceftriaxone 15/15 (100) 0 9/8 (89) 
Chloramphenicol 15/12 (80) 11/11 (100) 9/8 (89) 
Clindamycin 0 11/10 (91) 0 
Cotrimoxazole 15/14 (93) 0 9/6 (67) 
Gentamicin 15/7 (47) 0 9/4 (44) 
Levofloxacin 0 11/10 (91) 0 
Oxacillin 12/3 (25) 11/11 (100) 1/0 
Penicillin 15/15 (100) 11/10 (91) 9/5 (56) 
Rifampin 15/15 (100) 0 9/6 (67) 
Tetracycline 0 11/0 0 
*The regional bacteriology laboratory in Dapaong, Togo. 
†National Reference Center for Streptococci in Aachen, Germany. 
 
